Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer.

Trial Profile

Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PROSE
  • Most Recent Events

    • 02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 12 May 2014 Results published in the Lancet Oncology.
    • 04 Jun 2013 Primary endpoint 'Overall-survival' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top